Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study,Molecular Cancer Therapeutics

当前位置： X-MOL 学术 › Mol. Cancer Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
Molecular Cancer Therapeutics ( IF 5.7 ) Pub Date : 2021-09-01 , DOI: 10.1158/1535-7163.mct-20-1064
Hong Zheng ₁ , Yunong Gao ₁ , Hongyan Guo ₂ , Li Li ₃ , Qingshui Li ₄ , Heng Cui ₅ , An Lin ₆ , Lixin Sun ₇ , Yuanjing Hu ₈ , Shan Kang ₉ , Wei Duan ₁₀ , Lingya Pan ₁₁ , Shuzhen Wang ₁₂ , Yingjie Yang ₁₃ , Yunxia Li ₁₄ , Weimin Kong ₁₀ , Yang Xiang ₁₁ , Xiaofei Tian ₁₅ , Bin Ling ₁₆ , Chunfang Ha ₁₄ , Wenpei Bai ₁₇

Affiliation

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Department of Gynecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, P.R. China.
Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, P.R. China.
Department of Gynecologic Oncology, The Third Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital), Urumqi, P.R. China.
Department of Gynecology Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, P.R. China.
Department of Obstetrics and Gynecology, Center of Gynecologic Oncology, Peking University People's Hospital, Beijing, P.R. China.
Department of Gynecologic Oncology, Fujian Cancer Hospital, Fuzhou, P.R. China.
Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, P.R. China.
Department of Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China.
Department of Obstetrics and Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, P.R. China.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, P.R. China.
Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, P.R. China.
Department of Gynecologic Oncology, Guizhou Cancer Hospital, Guiyang, P.R. China.
Department of Obstetrics and Gynecology, General Hospital of Ningxia Medical University, Yinchuan, P.R. China.
Department of Gynecologic Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, P.R. China.
Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, P.R. China.
Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, P.R. China.

The objective of this study was to evaluate the real-world application, efficacy, and safety data of olaparib for maintenance therapy and active treatment in patients with ovarian cancer in China. Patients with ovarian cancer from 17 institutions in China treated with olaparib as maintenance or active therapy from January 2018 to March 2020 were included in this study. The medical records were reviewed, and follow-up information was collected for analysis of the patients' clinicopathologic characteristics as well as the effectiveness and safety of olaparib. A total of 251 patients receiving olaparib were included, with 84 as maintenance therapy after first-line chemotherapy (FL-M), 97 as maintenance therapy after platinum-sensitive recurrence (PSR-M), and 70 as active treatment (AT). The probability of progression-free survival (PFS) at 12 months was 87.6% in the FL-M group and 63.8% in the PSR-M group. According to the multivariate analysis, complete response (CR) to chemotherapy for the PSR-M patients was the only factor affecting the PFS (HR = 0.414, P = 0.014), and platinum sensitivity was the only factor affecting PFS improvement in the AT group (HR = 0.317, P = 0.009). In the AT group, the objective response rate was 37.1%, the CR rate was 7.1%, and 30% of the patients had stable disease. Eight (3.2%) patients discontinued olaparib due to toxicity. Anemia was the most common adverse event. In conclusion, olaparib is effective and well tolerated in the real-world setting of ovarian cancer treatment. Platinum sensitivity is positively correlated to the effectiveness of olaparib in both maintenance and active treatment.

更新日期：2021-09-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>